Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DFFN Diffusion Pharmaceuticals (DFFN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Diffusion Pharmaceuticals Stock (NASDAQ:DFFN) 30 days 90 days 365 days Advanced Chart Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get DFFN alerts:Sign Up Key Stats Today's Range N/A50-Day Range$4.38▼$6.6052-Week Range N/AVolume351,000 shsAverage Volume10,937 shsMarket Capitalization$8.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Receive DFFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DFFN Stock News HeadlinesComparing diffusion, osmosis and active transportApril 18, 2024 | bbc.co.ukDiffusion Pharmaceuticals Inc.February 10, 2024 | thestreet.comNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.November 21, 2024 | Darwin (Ad)Vertex co-founder Josh Boger joins Boston biotech working on dementia drugFebruary 8, 2024 | bizjournals.comStable Video Diffusion is now available through Stability AI APIDecember 22, 2023 | venturebeat.comDiffusion Pharmaceuticals Inc.: Diffusion Pharmaceuticals Stockholders Approve Merger with EIP PharmaAugust 16, 2023 | finanznachrichten.deDiffusion Pharmaceuticals Inc.: Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma / Announces 1-for-1.5 Reverse Stock SplitAugust 16, 2023 | finanznachrichten.deDiffusion Pharmaceuticals Stockholders Approve Merger with EIP PharmaAugust 15, 2023 | finance.yahoo.comSee More Headlines DFFN Stock Analysis - Frequently Asked Questions How were Diffusion Pharmaceuticals' earnings last quarter? Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($9.00) EPS for the quarter, missing the consensus estimate of ($3.00) by $6.00. When did Diffusion Pharmaceuticals' stock split? Shares of Diffusion Pharmaceuticals reverse split before market open on Thursday, August 17th 2023. The 1-1.5 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 67 shares after the split. What other stocks do shareholders of Diffusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Diffusion Pharmaceuticals investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), OPKO Health (OPK), T2 Biosystems (TTOO), NightHawk Biosciences (NHWK), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). Company Calendar Last Earnings11/10/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DFFN CUSIPN/A CIK1053691 Webwww.diffusionpharma.com Phone(434) 220-0718Fax434-220-0722Employees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.96% Return on Assets-62.98% Debt Debt-to-Equity RatioN/A Current Ratio10.71 Quick Ratio10.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / BookN/AMiscellaneous Outstanding Shares2,040,000Free Float2,003,000Market Cap$8.98 million OptionableNot Optionable Beta1.78 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:DFFN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diffusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Diffusion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
